(Reuters) -The U.S. Food and Drug Administration is probing the death of a patient who developed harmful antibodies after taking Takeda Pharmaceuticals' blood disorder therapy, the health regulator said on Friday.
The pediatric patient died about 10 months after starting Takeda's drug Adzynma as a preventive therapy, the agency said.
The child had congenital thrombotic thrombocytopenic purpura (cTTP), an inherited condition that causes blood clots in small vessels and can lead to organ damage.
The FDA said the child developed antibodies that blocked the activity of ADAMTS13, an enzyme critical for blood clotting.
Takeda did not immediately respond to Reuters request for comment.
Adzynma, approved in 2023 as the first therapy for cTTP, replaces the ADAMTS13 protein to help prevent dangerous blood clots.
The agency added it has received multiple postmarketing reports of patients developing neutralizing antibodies to ADAMTS13 after treatment with Adzynma.
(Reporting by Kamal Choudhury in Bengaluru; Editing by Vijay Kishore)
LATEST POSTS
- 1
St George Mining hits record 178m high-grade intercept at Araxá, reinforcing global scale - 2Mickey Lee of 'Big Brother' fame dead at 35 after flu complications, family says
- 3Physicists and philosophers have long struggled to understand the nature of time: Here's why
- 4New Jordan security fence could be done in early 2028
- 5'Wow!' The eye surgery marathon that restored sight for some South Africans
- Why boosting production of Venezuela's 'very dense, very sloppy' oil could harm the environment
- Moscow: Russia well-positioned to withstand oil market shocks
- Politics at the table? Drinking the wine you brought? An etiquette expert's Thanksgiving dos and don'ts.
- Ever Wonder What An EV Motorcycle Water Crossing Would Be Like? Here You Go
- 5 VIPs That Changed Style
- Does physics say that free will doesn't exist?
- ‘It’s Israeli policy’: Report reveals abuse of Palestinians in prisons
- Boeing's troubled capsule won't carry astronauts on next space station flight
- From Dread to Certainty: Individual Accounts of Strengthening
